Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

Jiao Liu(Third Affiliated Hospital of Guangzhou Medical University), Dechang Chen(Shanghai Jiao Tong University), Yanxia Huang(Shanghai Jiao Tong University), Qiang Zhao(Jilin University), Xiangdong Guan(Sun Yat-sen University), Quanhong Zhou(Shanghai Jiao Tong University), Yun Ling(Zhejiang Chinese Medical University), Zhenliang Wen(Shanghai Jiao Tong University), Xiaofei Ye(Second Military Medical University), Lidi Zhang(Shanghai Jiao Tong University), Yunfeng Wang(Shanghai University of Medicine and Health Sciences), Jieming Qu(Shanghai Jiao Tong University), Zhijie Xia(Fudan University), Lun–Xiu Qin(Fudan University), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Djillali Annane(Université Paris-Saclay), Hangxiang Du(Shanghai Jiao Tong University), Zi Ge(Fudan University), Ying Lv(Shanghai Public Health Clinical Center), Xiaojun Pan(Wenzhou Medical University), Xingqi Deng(Shanghai University of Medicine and Health Sciences), Ming Li(Nanjing Agricultural University), Xian Zhang(State Key Joint Laboratory of Environment Simulation and Pollution Control), Tao Wang(Shanghai Jiao Tong University), Wenzhe Li(Shanghai Jiao Tong University), Yi Yang(Zhongda Hospital Southeast University), Ke Ma(Fudan University), Sisi Huang(Shanghai Jiao Tong University), Ren Zhao(Shanghai Institute of Hematology), Sheng Zhang(Shanghai Jiao Tong University), Yizhu Chen(Shanghai Jiao Tong University), Tangkai Qi(Shanghai Public Health Clinical Center), Yongan Liu(Shanghai Jiao Tong University), Cunyi Fan(Shanghai Jiao Tong University)
The Lancet Regional Health - Western Pacific
February 5, 2023
Cited by 112


Related Papers